Novartis Says Chair Contradicted Admissions In FCA Deal
Novartis said its chairman incorrectly contradicted the company's admissions that it made as part of a $678 million deal with the federal government to settle claims it flouted the False Claims...To view the full article, register now.
Already a subscriber? Click here to view full article